News from us and our partners

Tags

Topics

0 results

News
13 December, 2022
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan
News
11 December, 2022
HitGen announces research agreement with Nitrase Therapeutics focused on DNA-encoded library based drug discovery
News
6 December, 2022
Moon Surgical receives first FDA 510(k) clearance for its Maestro(TM) Surgical Robotics System
News
6 December, 2022
FMC Corporation and Micropep Technologies announce strategic collaboration to co-develop bioherbicide solutions
News
29 November, 2022
Microphyt raises €15 million to accelerate the commercialization of its microalgae-based natural solutions for nutrition and well-being
News
28 November, 2022
CinCor Pharma announces topline data for Phase 2 HALO Trial evaluating selective aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension
News
21 November, 2022
Inventiva announces a new Director of the Board of Directors
News
15 November, 2022
Moon Surgical names Mark Toland as independent board member
News
14 November, 2022
Endoron Medical awarded a €2.5M grant from the European Commission through the prestigious EIC Accelerator Program
News
9 November, 2022
DNA Script appoints Bruno Poddevin as SVP business development
News
9 November, 2022
Sofinnova Partners appoints Mats Eklund as Partner and Chief Operating Officer
News
7 November, 2022
CinCor Pharma announces publication in the New England Journal of Medicine of Phase 2 BrigHtn data on selective aldosterone synthase inhibitor baxdrostat in treatment-resistant hypertension
News
7 November, 2022
Sensorion announces US FDA grants Rare Pediatric Disease Designation to OTOF-GT for the treatment of otoferlin gene-mediated hearing loss
News
25 October, 2022
Inotrem announces that its ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets its primary and key secondary endpoints
News
21 October, 2022
F2G announces data from Phase 2b study at ID Week 2022 showing positive therapeutic response in patients with invasive fungal infections treated with Olorofim
News
18 October, 2022
Noema Pharma receives FDA Fast Track designation for basimglurant (NOE-101) in trigeminal neuralgia

Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan

HitGen announces research agreement with Nitrase Therapeutics focused on DNA-encoded library based drug discovery

Moon Surgical receives first FDA 510(k) clearance for its Maestro(TM) Surgical Robotics System

FMC Corporation and Micropep Technologies announce strategic collaboration to co-develop bioherbicide solutions

Microphyt raises €15 million to accelerate the commercialization of its microalgae-based natural solutions for nutrition and well-being

CinCor Pharma announces topline data for Phase 2 HALO Trial evaluating selective aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension

Inventiva announces a new Director of the Board of Directors

Moon Surgical names Mark Toland as independent board member

Endoron Medical awarded a €2.5M grant from the European Commission through the prestigious EIC Accelerator Program

DNA Script appoints Bruno Poddevin as SVP business development

Sofinnova Partners appoints Mats Eklund as Partner and Chief Operating Officer

CinCor Pharma announces publication in the New England Journal of Medicine of Phase 2 BrigHtn data on selective aldosterone synthase inhibitor baxdrostat in treatment-resistant hypertension

Sensorion announces US FDA grants Rare Pediatric Disease Designation to OTOF-GT for the treatment of otoferlin gene-mediated hearing loss

Inotrem announces that its ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets its primary and key secondary endpoints

F2G announces data from Phase 2b study at ID Week 2022 showing positive therapeutic response in patients with invasive fungal infections treated with Olorofim

Noema Pharma receives FDA Fast Track designation for basimglurant (NOE-101) in trigeminal neuralgia